Pharmsynthez Stock

Equities

LIFE

RU000A0JR514

Pharmaceuticals

End-of-day quote Moscow Micex - RTS 06:00:00 2022-07-07 pm EDT 5-day change 1st Jan Change
4.505 RUB +10.15% Intraday chart for Pharmsynthez -.--% -.--%
Sales 2021 438M 4.76M Sales 2022 380M 4.12M Capitalization 1.36B 14.73M
Net income 2021 -698M -7.58M Net income 2022 -207M -2.25M EV / Sales 2021 5.43 x
Net Debt 2021 693M 7.53M Net Debt 2022 736M 8M EV / Sales 2022 5.51 x
P/E ratio 2021
-2.42 x
P/E ratio 2022
-6.53 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 95.22%
More Fundamentals * Assessed data
Dynamic Chart
Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt CI
Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Public Joint-Stock Company "Pharmsynthez" announced that it expects to receive funding from Central Bank of the Russian Federation CI
Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt CI
Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Xenetic Biosciences, Inc. Enters into Amendment Number One to Master Services Agreement with PJSC Pharmsynthez CI
Market Chatter: South Korean Regulator Rejects Thelma Therapeutics's Phase Three Trial for COVID-19 Cure MT
Public Joint-Stock Company Pharmsynthez Reports Earnings Results for the Full Year Ended December 31, 2018 CI
PJSC Pharmsynthez Starts the Registration Phase of Epolong CI
HiFiBiO Therapeutics Inks Partnership with Pharmsynthez and IBCh for the Clinical Development and Commercialization of its SARS-CoV-2 Neutralizing Antibody in Russia CI
Public Joint-Stock Company "Pharmsynthez" acquired remaining unknown minority stake in VAKTSINY. CI
Xenetic Biosciences, Inc. and PJSC Pharmsynthez Enters into Master Service Agreement to Advance the Development of Xcart Technology CI
Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt CI
Pharmsynthez Appoints Members of Audit Commission CI
Rusnano To Sell Its Stake In Pharmsynthez CI
More news
3 years
2.65
Extreme 2.645
7.00
5 years
2.65
Extreme 2.645
10.85
10 years
2.65
Extreme 2.645
25.45
More quotes
Managers TitleAgeSince
Chief Executive Officer 46 12-12-31
Director of Finance/CFO 45 04-12-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 45 06-12-31
Director/Board Member 44 12-12-31
Chairman 56 04-12-31
More insiders
Farmsintez PAO (Farmsintez OJSC) is a Russia-based company, which is engaged in the pharmaceutical sector. The Company focuses on the medical research, development and manufacture of drugs ingredients used in oncology, gynecology, tuberculosis therapy and others. In addition, Farmsintez OAO offers chemical research services, chemical technology development and quality control services. The Company sells its products domestically, as well as abroad, including the Commonwealth of Independence State (CIS) countries. It has two wholly owned subsidiaries located in Moscow and Tallin, Estonia. As of May 21, 2011, the Company’s major shareholder was EphaG AS with a stake of 69.23%. In April 2013, the Company acquired the pharmacies of Guardum Pharmaceuticals in the U.S. state of Florida.
More about the company